Neurotoxicity of contrast media for magnetic resonance imaging after generalized breakdown of the blood-brain barrier.
Evill
C A
CA
Department of Radiology, Flinders Medical Centre, Adelaide, South Australia, Australia.
Wilson
A J
AJ
Fletcher
M C
MC
Sage
M R
MR
D000818:Animals; D001089:Arabinose / Q000494:pharmacology; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D003287:Contrast Media / Q000493:pharmacokinetics / Q000633:toxicity*; D004569:Electroencephalography / Q000187:drug effects; D005682:Gadolinium; D019786:Gadolinium DTPA; D006571:Heterocyclic Compounds / Q000493:pharmacokinetics / Q000633:toxicity*; D008279:Magnetic Resonance Imaging; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000633:toxicity*; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity; D011817:Rabbits; D012640:Seizures / Q000139:chemically induced
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D004369:Pentetic Acid; D005682:Gadolinium; D001089:Arabinose; D019786:Gadolinium DTPA